Eli Lilly’s U.S. stocks pre-market fell over 2%, currently at $1,036.20; on the news, Novo Nordisk will cut the price of semaglutide (Wegovy) by 50%, to $675 per month.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eli Lilly's US stocks drop over 2% in pre-market trading
Eli Lilly’s U.S. stocks pre-market fell over 2%, currently at $1,036.20; on the news, Novo Nordisk will cut the price of semaglutide (Wegovy) by 50%, to $675 per month.